OBJECTIVES: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation. BACKGROUND: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result. METHODS: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1 cm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported. RESULTS: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival. CONCLUSIONS: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.
OBJECTIVES: To describe the survival outcome of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic complete response (pCR) following neoadjuvant chemoradiation. BACKGROUND: Patients with BR/LA-PDAC are often treated with neoadjuvant chemoradiation in an attempt to downstage the tumor. Uncommonly, a pCR may result. METHODS: A retrospective review of a prospectively maintained database was performed at a single institution. pCR was defined as no viable tumor identified in the pancreas or lymph nodes by pathology. A near complete response (nCR) was defined as a primary tumor less than 1 cm, without nodal metastasis. Overall survival (OS) and disease-free survival (DFS) were reported. RESULTS: One hundred eighty-six patients with BR/LA-PDAC underwent neoadjuvant chemoradiation and subsequent pancreatectomy. Nineteen patients (10%) had a pCR, 29 (16%) had an nCR, and the remaining 138 (74%) had a limited response. Median DFS was 26 months in patients with pCR, which was superior to nCR (12 months, P = 0.019) and limited response (12 months, P < 0.001). The median OS of nCR (27 months, P = 0.003) or limited response (26 months, P = 0.001) was less than that of pCR (more than 60 months). In multivariable analyses pCR was an independent prognostic factor for DFS (HR = 0.45; 0.22-0.93, P = 0.030) and OS (HR=0.41; 0.17-0.97, P = 0.044). Neoadjuvant FOLFIRINOX (HR=0.47; 0.26-0.87, P = 0.015) and negative lymph node status (HR=0.57; 0.36-0.90, P = 0.018) were also associated with improved survival. CONCLUSIONS: Patients with BR/LA-PDAC who had a pCR after neoadjuvant chemoradiation had a significantly prolonged survival compared with those who had nCR or a limited response.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: Ann Surg Date: 2015-01 Impact factor: 12.969
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: Felipe A Calvo; Raúl Matute; José Luis García-Sabrido; Marina Gómez-Espí; Nuria E Martínez; Miguel A Lozano; Rafael Herranz Journal: Am J Clin Oncol Date: 2004-08 Impact factor: 2.339
Authors: Michael D Chuong; Jessica M Frakes; Nicholas Figura; Sarah E Hoffe; Ravi Shridhar; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Gregory M Springett; Barbara A Centeno Journal: J Gastrointest Oncol Date: 2016-04
Authors: Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-05 Impact factor: 7.038
Authors: Aaron T Wild; Joseph M Herman; Avani S Dholakia; Shalini Moningi; Yao Lu; Lauren M Rosati; Amy Hacker-Prietz; Ryan K Assadi; Ali M Saeed; Timothy M Pawlik; Elizabeth M Jaffee; Daniel A Laheru; Phuoc T Tran; Matthew J Weiss; Christopher L Wolfgang; Eric Ford; Stuart A Grossman; Xiaobu Ye; Susannah G Ellsworth Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-01 Impact factor: 7.038
Authors: Malolan S Rajagopalan; Dwight E Heron; Rodney E Wegner; Herbert J Zeh; Nathan Bahary; Alyssa M Krasinskas; Barry Lembersky; Randall Brand; A James Moser; Annette E Quinn; Steven A Burton Journal: Radiat Oncol Date: 2013-10-31 Impact factor: 3.481
Authors: Jae P Jung; Mazen S Zenati; Ahmad Hamad; Melissa E Hogg; Richard L Simmons; Amer H Zureikat; Herbert J Zeh; Brian A Boone Journal: HPB (Oxford) Date: 2018-11-28 Impact factor: 3.647
Authors: Georgios Gemenetzis; Alex B Blair; Minako Nagai; William R Burns; Christopher L Wolfgang; Jin He; Vincent P Groot; Ding Ding; Ammar A Javed; Richard A Burkhart; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; John L Cameron; Amol Narang; Daniel Laheru; Kelly Lafaro; Joseph M Herman; Lei Zheng Journal: Ann Surg Oncol Date: 2021-08-27 Impact factor: 5.344
Authors: Douglas S Swords; Samual R Francis; Shane Lloyd; Ignacio Garrido-Laguna; Sean J Mulvihill; Joshua D Gruhl; Miles C Christensen; Gregory J Stoddard; Matthew A Firpo; Courtney L Scaife Journal: J Gastrointest Surg Date: 2018-09-05 Impact factor: 3.452
Authors: Thomas Hank; Marta Sandini; Cristina R Ferrone; Clifton Rodrigues; Maximilian Weniger; Motaz Qadan; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-Del Castillo Journal: JAMA Surg Date: 2019-10-01 Impact factor: 14.766
Authors: Derek J Erstad; Mozhdeh Sojoodi; Martin S Taylor; Veronica Clavijo Jordan; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs; Christian T Farrar; Andrea L Axtell; Nicholas J Rotile; Chloe Jones; Katherine A Graham-O'Regan; Diego S Ferreira; Theodoros Michelakos; Filippos Kontos; Akhil Chawla; Shen Li; Sarani Ghoshal; Yin-Ching Iris Chen; Gunisha Arora; Valerie Humblet; Vikram Deshpande; Motaz Qadan; Nabeel Bardeesy; Cristina R Ferrone; Michael Lanuti Journal: Clin Cancer Res Date: 2020-07-01 Impact factor: 12.531
Authors: Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas Journal: CA Cancer J Clin Date: 2020-07-19 Impact factor: 508.702